98 related articles for article (PubMed ID: 27806630)
1. Deregulated miRNAs in human cervical cancer: functional importance and potential clinical use.
Li J; Liu Q; Clark LH; Qiu H; Bae-Jump VL; Zhou C
Future Oncol; 2017 Apr; 13(8):743-753. PubMed ID: 27806630
[TBL] [Abstract][Full Text] [Related]
2. MicroRNAs are involved in cervical cancer development, progression, clinical outcome and improvement treatment response (Review).
González-Quintana V; Palma-Berré L; Campos-Parra AD; López-Urrutia E; Peralta-Zaragoza O; Vazquez-Romo R; Pérez-Plasencia C
Oncol Rep; 2016 Jan; 35(1):3-12. PubMed ID: 26530778
[TBL] [Abstract][Full Text] [Related]
3. Survival‑related DLEU1 is associated with HPV infection status and serves as a biomarker in HPV‑infected cervical cancer.
Dong A; Xu B; Wang Z; Miao X
Mol Med Rep; 2022 Mar; 25(3):. PubMed ID: 35014679
[TBL] [Abstract][Full Text] [Related]
4. [The role of microRNAs in the pathogenesis of cervical cancer and its relationship to HPV].
Zhu YK; Cheng N; Hu Y; Cen YZ
Sheng Li Ke Xue Jin Zhan; 2012 Aug; 43(4):251-6. PubMed ID: 23189617
[TBL] [Abstract][Full Text] [Related]
5. Cervical cancer development, chemoresistance, and therapy: a snapshot of involvement of microRNA.
Mitra T; Elangovan S
Mol Cell Biochem; 2021 Dec; 476(12):4363-4385. PubMed ID: 34453645
[TBL] [Abstract][Full Text] [Related]
6. A review on the role of epidermal growth factor signaling in the development, progression and treatment of cervical cancer.
Muthusami S; Sabanayagam R; Periyasamy L; Muruganantham B; Park WY
Int J Biol Macromol; 2022 Jan; 194():179-187. PubMed ID: 34848237
[TBL] [Abstract][Full Text] [Related]
7. Deregulation of the miRNAs expression in cervical cancer: human papillomavirus implications.
Gómez-Gómez Y; Organista-Nava J; Gariglio P
Biomed Res Int; 2013; 2013():407052. PubMed ID: 24490161
[TBL] [Abstract][Full Text] [Related]
8. A systematic study on dysregulated microRNAs in cervical cancer development.
He Y; Lin J; Ding Y; Liu G; Luo Y; Huang M; Xu C; Kim TK; Etheridge A; Lin M; Kong D; Wang K
Int J Cancer; 2016 Mar; 138(6):1312-27. PubMed ID: 26032913
[TBL] [Abstract][Full Text] [Related]
9. MicroRNAs in the development and pathobiology of uterine leiomyomata: does evidence support future strategies for clinical intervention?
Karmon AE; Cardozo ER; Rueda BR; Styer AK
Hum Reprod Update; 2014; 20(5):670-87. PubMed ID: 24706045
[TBL] [Abstract][Full Text] [Related]
10. Human papillomavirus (HPV) screening and cervical cancer burden. A Brazilian perspective.
Lorenzi AT; Syrjänen KJ; Longatto-Filho A
Virol J; 2015 Jul; 12():112. PubMed ID: 26208521
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus confers radiosensitivity in cancer cervix: a hypothesis toward a possible restoration of apoptotic pathways based on clinical outcomes.
Datta NR; Singh S; Kumar P; Gupta D
Future Oncol; 2015; 11(9):1363-71. PubMed ID: 25952782
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of miR-1246 in cervical cancer tissues and its clinical significance.
Yang Y; Xie YJ; Xu Q; Chen JX; Shan NC; Zhang Y
Gynecol Oncol; 2015 Sep; 138(3):683-8. PubMed ID: 26074491
[TBL] [Abstract][Full Text] [Related]
13. The roles and clinical significance of microRNAs in cervical cancer.
Wang F; Li B; Xie X
Histol Histopathol; 2016 Feb; 31(2):131-9. PubMed ID: 26356641
[TBL] [Abstract][Full Text] [Related]
14. miR-375 Modulates Radiosensitivity of HR-HPV-Positive Cervical Cancer Cells by Targeting UBE3A through the p53 Pathway.
Song L; Liu S; Zeng S; Zhang L; Li X
Med Sci Monit; 2015 Jul; 21():2210-7. PubMed ID: 26224081
[TBL] [Abstract][Full Text] [Related]
15. Role of miRNAs in cervical cancer: A comprehensive novel approach from pathogenesis to therapy.
Abbas M; Mehdi A; Khan FH; Verma S; Ahmad A; Khatoon F; Raza ST; Afreen S; Glynn SA; Mahdi F
J Gynecol Obstet Hum Reprod; 2021 Nov; 50(9):102159. PubMed ID: 33965650
[TBL] [Abstract][Full Text] [Related]
16. miRNAs role in cervical cancer pathogenesis and targeted therapy: Signaling pathways interplay.
Doghish AS; Ali MA; Elyan SS; Elrebehy MA; Mohamed HH; Mansour RM; Elgohary A; Ghanem A; Faraag AHI; Abdelmaksoud NM; Moustafa HAM
Pathol Res Pract; 2023 Apr; 244():154386. PubMed ID: 36868096
[TBL] [Abstract][Full Text] [Related]
17. Gene identification by cDNA arrays in HPV-positive cervical cancer.
Vázquez-Ortíz G; Ciudad CJ; Piña P; Vazquez K; Hidalgo A; Alatorre B; Garcia JA; Salamanca F; Peralta-Rodriguez R; Rangel A; Salcedo M
Arch Med Res; 2005; 36(5):448-58. PubMed ID: 16099320
[TBL] [Abstract][Full Text] [Related]
18. Activation of miR-9 by human papillomavirus in cervical cancer.
Liu W; Gao G; Hu X; Wang Y; Schwarz JK; Chen JJ; Grigsby PW; Wang X
Oncotarget; 2014 Nov; 5(22):11620-30. PubMed ID: 25344913
[TBL] [Abstract][Full Text] [Related]
19. Breaking the DNA damage response to improve cervical cancer treatment.
Wieringa HW; van der Zee AG; de Vries EG; van Vugt MA
Cancer Treat Rev; 2016 Jan; 42():30-40. PubMed ID: 26643553
[TBL] [Abstract][Full Text] [Related]
20. Human papillomavirus 16-positive uterine cervical squamous cell carcinoma with coinfection with human papillomavirus 34 has a lower incidence in lymph node metastasis than that without coinfection with human papillomavirus 34.
Michimata R; Watari H; Tomaru U; Sakuragi N; Ishizu A
Pathobiology; 2013; 80(5):259-64. PubMed ID: 23689419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
